Quest Partners LLC Acquires New Holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

Quest Partners LLC bought a new position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,926 shares of the company’s stock, valued at approximately $50,000.

A number of other large investors have also recently added to or reduced their stakes in VRCA. Key Financial Inc acquired a new stake in shares of Verrica Pharmaceuticals in the second quarter worth $69,000. Rhumbline Advisers lifted its position in Verrica Pharmaceuticals by 20.4% during the 2nd quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock worth $194,000 after acquiring an additional 4,514 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Verrica Pharmaceuticals by 8.1% during the second quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock valued at $428,000 after acquiring an additional 4,393 shares during the period. Vanguard Group Inc. boosted its holdings in Verrica Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock valued at $7,511,000 after acquiring an additional 7,609 shares during the period. Finally, Avoro Capital Advisors LLC grew its position in shares of Verrica Pharmaceuticals by 35.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 3,999,999 shares of the company’s stock valued at $29,280,000 after purchasing an additional 1,045,935 shares during the last quarter. Institutional investors own 42.45% of the company’s stock.

Insider Buying and Selling

In other Verrica Pharmaceuticals news, insider Joe Bonaccorso sold 25,461 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $7.06, for a total value of $179,754.66. Following the sale, the insider now owns 106,931 shares of the company’s stock, valued at approximately $754,932.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Joe Bonaccorso sold 25,461 shares of Verrica Pharmaceuticals stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $7.06, for a total transaction of $179,754.66. Following the sale, the insider now directly owns 106,931 shares in the company, valued at approximately $754,932.86. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Ted White sold 32,469 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $7.06, for a total transaction of $229,231.14. Following the completion of the sale, the chief executive officer now directly owns 250,121 shares in the company, valued at approximately $1,765,854.26. The disclosure for this sale can be found here. 42.60% of the stock is owned by company insiders.

Verrica Pharmaceuticals Stock Up 4.5 %

NASDAQ VRCA opened at $1.85 on Thursday. Verrica Pharmaceuticals Inc. has a twelve month low of $1.77 and a twelve month high of $11.41. The stock has a market cap of $78.94 million, a PE ratio of -1.03 and a beta of 1.48. The firm has a 50-day simple moving average of $4.58 and a 200 day simple moving average of $6.24. The company has a debt-to-equity ratio of 29.58, a quick ratio of 2.23 and a current ratio of 2.36.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $4.70 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. On average, research analysts forecast that Verrica Pharmaceuticals Inc. will post -1.56 EPS for the current year.

Wall Street Analyst Weigh In

VRCA has been the subject of several research analyst reports. Royal Bank of Canada cut their price objective on Verrica Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. Needham & Company LLC cut their price target on Verrica Pharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 15th.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.